Showing 1 - 10 of 437,422
The use of "pay-for-delay" settlements in patent litigation - in which a branded manufacturer and generic entrant … settle a Paragraph IV patent challenge and agree to forestall entry - has come under considerable scrutiny in recent years … instruments include standard measures of patent strength and a measure of settlement legality based on a split between several …
Persistent link: https://www.econbiz.de/10012456481
The use of so-called “pay-for-delay” settlements in patent litigation – in which a branded manufacturer and generic … entrant settle a Paragraph IV patent challenge and agree to forestall entry – has come under considerable scrutiny in recent … settlements we estimate the model using instrumental variables. Our instruments include standard measures of patent strength and a …
Persistent link: https://www.econbiz.de/10012988266
The use of “pay-for-delay” settlements in patent litigation – in which a branded manufacturer and generic entrant … settle a Paragraph IV patent challenge and agree to forestall entry – has come under considerable scrutiny in recent years … instruments include standard measures of patent strength and a measure of settlement legality based on a split between several …
Persistent link: https://www.econbiz.de/10012993248
The use of “pay-for-delay” settlements in patent litigation – in which a branded manufacturer and generic entrant … settle a Paragraph IV patent challenge and agree to forestall entry – has come under considerable scrutiny in recent years … instruments include standard measures of patent strength and a measure of settlement legality based on a split between several …
Persistent link: https://www.econbiz.de/10014083301
Persistent link: https://www.econbiz.de/10012433661
Persistent link: https://www.econbiz.de/10012182277
Persistent link: https://www.econbiz.de/10015419426
We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive control drugs. Our analysis highlights (i) the...
Persistent link: https://www.econbiz.de/10012670921
"While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan...
Persistent link: https://www.econbiz.de/10011602926
Persistent link: https://www.econbiz.de/10013483844